These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9363046)

  • 21. [Placebo effect and relief of anxiety].
    Olié JP; Vanelle JM
    Encephale; 1983; 9(4 Suppl 2):231B-235B. PubMed ID: 6144518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
    Khan A; Schwartz K; Kolts RL; Ridgway D; Lineberry C
    Biol Psychiatry; 2007 Jul; 62(1):65-71. PubMed ID: 17141744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comments on article by Mitte and associates: "A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder".
    Magalhães PV
    J Clin Psychopharmacol; 2006 Apr; 26(2):220-1; author reply 221. PubMed ID: 16633161
    [No Abstract]   [Full Text] [Related]  

  • 25. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
    Pollack MH; Tiller J; Xie F; Trivedi MH
    J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P; Touchon J; Billardon M
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical presentation of generalized anxiety in primary-care settings: practical concepts of classification and management.
    Rickels K; Schweizer E
    J Clin Psychiatry; 1997; 58 Suppl 11():4-10. PubMed ID: 9363042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The patient with comorbid depression and anxiety: the unmet need.
    Bakish D
    J Clin Psychiatry; 1999; 60 Suppl 6():20-4. PubMed ID: 10235121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
    Russell JM; Weisberg R; Fava M; Hartford JT; Erickson JS; D'Souza DN
    Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies.
    Pollack MH; Meoni P; Otto MW; Simon N; Hackett D
    J Clin Psychopharmacol; 2003 Jun; 23(3):250-9. PubMed ID: 12826987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generalized anxiety disorder versus panic disorder: participation in controlled efficacy trials.
    Mavissakalian MR; Zamar N
    Compr Psychiatry; 2000; 41(4):253-8. PubMed ID: 10929792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder.
    DeMartinis N; Rynn M; Rickels K; Mandos L
    J Clin Psychiatry; 2000 Feb; 61(2):91-4. PubMed ID: 10732655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Results of a cooperative study of bromazepam involving 3.401 ambulatory psychiatric patients and 8.191 patients from general practice (author's transl)].
    Perrier F
    Nouv Presse Med; 1982 May; 11(22):1747-51. PubMed ID: 6124950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot investigation of clinical effects of PM-33, a new anti-anxiety agent.
    Abuzzahab FS; Kulkarni AS
    Curr Ther Res Clin Exp; 1974 Nov; 16(11):1181-6. PubMed ID: 4154180
    [No Abstract]   [Full Text] [Related]  

  • 38. Pregabalin: dose-response relationship in generalized anxiety disorder.
    Boschen MJ
    Pharmacopsychiatry; 2012 Mar; 45(2):51-6. PubMed ID: 22086745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brief treatment of anxious patients with halazepam in high doses [proceedings].
    Kellner R; Bruzzese D; Winslow WW
    Psychopharmacol Bull; 1977 Apr; 13(2):21-2. PubMed ID: 16309
    [No Abstract]   [Full Text] [Related]  

  • 40. Surprising results in the study of paroxetine for generalized anxiety disorder.
    Ballas CA
    J Clin Psychiatry; 2002 Jun; 63(6):536; author reply 536-7. PubMed ID: 12088169
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.